Citations

Clear

1526 citation(s) found for "Sun, C".

Looking Back: International Practice Patterns in Breast Radiation Oncology From a Case-Based Survey Across 54 Countries During the First Surge of the COVID-19 Pandemic
Dunn, Samantha A., Li, Jian , Coles, Charlotte E. , Yamauchi, Chikako , Chang, Jee Suk , Cheng, Skye Hung‐Chun , Meattini, Icro , Ramiah, Duvern , Hijal, Tarek , Poortmans, Philip , Isern, J. , Zissiadis, Yvonne , Offersen, Birgitte Vrou , Hijazi, Hussam, Dengina, Natalia , Belkacémi, Yazid , Luo, Feng, Griffin, Colleen, Collins, Maya, Larios, Dalia, Punglia, Rinaa S. , Wong, Julia S., Spiegel, Daphna Y. , Bellon, Jennifer R. , Ho, Alice Y. , Oladeru, Oluwadamilola T , Yamauchi, Chikako , Chang, Jee Suk , Cheng, Skye Hung-Chun , Kaidar-Person, Orit , Meattini, Icro , Kirby, Anna , Hijal, Tarek , Marta, Gustavo Nader , Isern-Verdum, Josep , Offersen, Birgitte Vrou , Elsayad, Khaled , Lu, Shun , Punglia, Rinaa S , Spiegel, Daphna Y , Jagsi, Reshma , Taghian, Alphonse , Bellon, Jennifer R , Ho, Alice Y , Oladeru, Oluwadamilola T. , Refaat, Tamer , Ryan, Phoebe K. , Warren, Laura Elizabeth , Jagsi, Reshma

Mayo Clinic

JCO Global Oncology | July 20, 2023 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/go.23.00010 | PMID 37471670 Get It

PURPOSE The COVID-19 pandemic has profoundly affected cancer care worldwide, including radiation therapy (RT) for breast cancer (BC), because of risk-based resource allocation. We report the evolution of international breast RT practices during the beginning of the pandemic, focusing on differences in treatment recommendations between countries. MATERIALS AND METHODS Between July and November 2020, a 58-question survey was distributed to radiation oncologists (ROs) through international professional societies. Changes in RT decision making during the first surge of the pandemic were evaluated across six hypothetical scenarios, including the management of ductal carcinoma in situ (DCIS), early-stage, locally advanced, and metastatic BC. The significance of changes in responses before and during the pandemic was examined using chi-square and McNemar-Bowker tests. RESULTS One thousand one hundred three ROs from 54 countries completed the survey. Incomplete responses (254) were excluded from the analysis. Most respondents were from the United States (285), Japan (117), Italy (63), Canada (58), and Brazil (56). Twenty-one percent (230) of respondents reported treating at least one patient with BC who was COVID-19–positive. Approximately 60% of respondents reported no change in treatment recommendation during the pandemic, except for patients with metastatic disease, for which 57.7% (636/1,103; P < .0005) changed their palliative practice. Among respondents who noted a change in their recommendation during the first surge of the pandemic, omitting, delaying, and adopting short-course RT were the most frequent changes, with most transitioning to moderate hypofractionation for DCIS and early-stage BC. CONCLUSION Early in the COVID-19 pandemic, significant changes in global RT practice patterns for BC were introduced. The impact of published results from the FAST FORWARD trial supporting ultrahypofractionation likely confounded the interpretation of the pandemic's independent influence on RT delivery.
Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort
Choudhury, Parichita , Belden, Christine M. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Shill, Holly A. , Beach, Thomas G. , Driver-Dunckley, Erika, Choudhury, Parichita , Zhang, Nan , Adler, Charles H. , Chen, Kewei , Driver‐Dunckley, Erika , Shprecher, David , Serrano, Geidy E. , Atri, Alireza

Mayo Clinic

Alzheimer's & Dementia | July 8, 2023 | Volume: 19 | Issue: 10 | Pages: 4377-4387

10.1002/alz.13357 | PMID 37422286 Get It

Abstract INTRODUCTION We examined the progression of extrapyramidal symptoms and signs in autopsy‐confirmed dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and Alzheimer's disease dementia (AD). METHODS Longitudinal data were obtained from Arizona Study of Aging and Neurodegenerative Disease, with PDD ( n = 98), AD ( n = 47) and DLB ( n = 48) further sub‐grouped as with or without parkinsonism (DLB+ and DLB−). Within‐group Unified Parkinson's Disease Rating Scale (UPDRS) ‐II and UPDRS‐III trajectories were analyzed using non‐linear mixed effects models. RESULTS In DLB, 65.6% had parkinsonism. Baseline UPDRS‐II and III scores (off‐stage) were highest ( P < 0.001) for PDD (mean ± SD 14.3 ± 7.8 and 27.4 ± 16.3), followed by DLB+ (6.0 ± 8.8 and 17.2 ± 17.1), DLB− (1.1 ± 1.3 and 3.3 ± 5.5) and AD (3.2 ± 6.1 and 8.2 ± 13.6). Compared to PDD, the DLB+ group had faster UPDRS‐III progression over 8‐years (Cohen's‐ d range 0.98 to 2.79, P < 0.001), driven by gait ( P < 0.001) and limb bradykinesia ( P = 0.02) subscales. DISCUSSION Motor deficits progress faster in DLB+ than PDD, providing insights about expected changes in motor function. Highlights Dementia with Lewy bodies has faster motor progression than Parkinson's disease dementia Linear and non‐linear mixed modeling analysis of longitudinal data was utilized Findings have implications for clinical prognostication and trial design
Mesenchymal Stem/Stromal Cells Therapy for Metabolic Syndrome: Potential Clinical Application?
Huang, Xiuyi , Liu, Yunchong , Li, Zilun , Lerman, Lilach O.

Mayo Clinic

Stem Cells | July 6, 2023 | Volume: 41 | Issue: 10 | Pages: 893-906

10.1093/stmcls/sxad052 | PMID 37407022 Get It

Abstract Mesenchymal stem/stromal cells (MSCs), a class of cells with proliferative, immunomodulatory, and reparative functions, have shown therapeutic potential in a variety of systemic diseases, including metabolic syndrome (MetS). The cluster of morbidities that constitute MetS might be particularly amenable for the application of MSCs, which employ an arsenal of reparative actions to target multiple pathogenic pathways simultaneously. Preclinical studies have shown that MSCs can reverse pathological changes in MetS mainly by inhibiting inflammation, improving insulin resistance, regulating glycolipid metabolism, and protecting organ function. However, several challenges remain to overcome before MSCs can be applied for treating MetS. For example, the merits of autologous versus allogeneic MSCs sources remain unclear, particularly with autologous MSCs obtained from the noxious MetS milieu. The distinct characteristics and relative efficacy of MSCs harvested from different tissue sources also require clarification. Moreover, to improve the therapeutic efficacy of MSCs, investigators have explored several approaches that improved therapeutic efficacy but may involve potential safety concerns. This review summarized the potentially useful MSCs strategy for treating MetS, as well as some hurdles that remain to be overcome. In particular, larger-scale studies are needed to determine the therapeutic efficacy and safety of MSCs for clinical application.
Ultrasound‐targeted microbubble destruction mediates PDE5i/NO integration for cavernosum remodeling and penile rehabilitation
Yang, Wende, Qiu, Chen , Zhai, Jiancheng , Zhang, Wei, Shao, Jun , Zhang, Jingke , Chen, Shigao , Miao, Xiaoyan , Ren, Jie , Wei, Hongbo , Zhang, Jingke , Huang, Chengwu , Chen, Peng, Wei, Bo

Mayo Clinic

Bioengineering & Translational Medicine | July 3, 2023 | Volume: 8 | Issue: 5 | Pages: No page available

10.1002/btm2.10568 | PMID 37693040 Get It

AbstractErectile dysfunction (ED) caused by cavernous nerve injury (CNI) is refractory to heal mainly ascribed to the adverse remodeling of the penis induced by ineffectual microvascular perfusion, fibrosis, and neurotrophins scarcity in cavernosum. Phosphodiesterase type V inhibitors (PDE5i) have been regarded as an alternative candidate drug for avoiding penile neuropathy. However, the therapeutic efficacy is severely limited due to poor accumulation under systemic medication and endogenous nitric oxide (NO) deficiency in cavernosum. Herein, an innovative liposomal microbubble (MB) loaded with both Sildenafil (one of PDE5i) and NO was designed. Ultrasound‐targeted MB destruction (UTMD)‐mediated efficient release and integration erectogenic agents into corpus cavernosum with high biosafety. On a bilateral CNI rat model, the multifunctional MB‐cooperated UTMD improved microvascular perfusion in penis, simultaneously, alleviated hypoxia and oxidative stress, indicating successful activation of NO–cyclic guanosine monophosphate pathway. Also, evaluation of the endothelial/muscular composition, intracavernosal pressure, and neural integrity in the penis proved that coordinated intervention reversed the abnormal structural remodeling and promoted the recovery of functional erection. Our work demonstrates that MB loading Sildenafil and NO combined with UTMD hold great promise to “awaken” the efficacy of PDE5i in neurogenic ED, which provided a superior option for ensuring penile rehabilitation.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, Mary E. , Lazarus, Jeffrey V. , Kanwal, Fasiha , Anstee, Quentin M. , Beuers, Ulrich , Boursier, Jérôme , Castro‐Narro, Graciela , Chowdhury, Abhijit , Cortez‐Pinto, Helena , Cryer, Donna R. , Cusi, Kenneth , Eskridge, Wayne , Fan, Jian‐Gao , Guy, Cynthia D. , Kim, Seung Up , Koot, Bart G.P. , Korenjak, Marko, Lacaille, Florence , Mitchell-Thain, Robert , Morgan, Timothy R. , Powell, Elisabeth E., Silva, Marcelo , Tiniakos, Dina, Valenti, Luca , Vos, Miriam B. , Xanthakos, Stavra A. , Yılmaz, Yusuf , Younossi, Zobair M. , Hobbs, Ansley, Newsome, Philip N. , group, on behalf of the NAFLD Nomenclature consensus, Trauner, Michael , Mato, José M. , Alves‐Bezerra, Michele , Thiele, Maja , Crespo, Javier , Alswat, Khalid , Abdelmalek, Manal F. , Valenti, Luca , Lazarus, Jeffrey V , Newsome, Philip N , Anstee, Quentin M , Rinella, Mary , Yilmaz, Yusuf , Castro-Narro, Graciela E , Cortez-Pinto, Helena , Thiele, Maja , Crespo, Javier , Ratziu, Vlad , Francque, Sven , Sanyal, Arun J. , Romero, Diana , Arab, Juan Pablo , Arrese, Marco , Bataller, Ramon A , Bugianesi, Elisabetta , Byrne, Christopher D. , El‐Kassas, Mohamed , Klein, Samuel , Gawrieh, Samer , Harrison, Stephen A. , Korenjak, Marko , Kowdley, Kris V. , Loomba, Rohit , Roden, Michael , Romero-Gómez, Manuel , Singh, Shivaram Prasad , Sookoian, Silvia C. , Spearman, C Wendy , Wong, Vincent Wai‐Sun , Villota‐Rivas, Marcela , group, on behalf of the NAFLD Nomenclature consensus

Mayo Clinic

Hepatology | June 22, 2023 | Volume: 78 | Issue: 6 | Pages: 1966-1986

10.1097/hep.0000000000000520 | PMID 37363821 Get It

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms “nonalcoholic” and “fatty” were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction–associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction–associated steatotic liver disease, who consume greater amounts of alcohol per week (140–350 g/wk and 210–420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and can improve awareness and patient identification.
Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome
Tora, Rana, Welch, James, Agarwal, Sunita , Bell, Debra A., Merino, Maria J. , Simonds, William F. , Simonds, William F , Jha, Smita , Sun, Jian Hong , Weinstein, Lee Scott

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | June 19, 2023 | Volume: 108 | Issue: 12 | Pages: 3165-3177

10.1210/clinem/dgad368 | PMID 37339334 Get It

Abstract Context Hyperparathyroidism-jaw tumor (HPT-JT) syndrome is a heritable form of primary hyperparathyroidism caused by germline inactivating mutations in CDC73 encoding parafibromin and is associated with an increased risk of parathyroid cancer. There is little evidence to guide the management of patients with the disease. Objective (1) Characterize the natural history of HPT-JT, (2) correlate genotype and histology of parathyroid tumors with parafibromin immunostaining, (3) understand molecular changes downstream to CDC73 loss. Design Retrospective study of patients with HPT-JT syndrome (genetically confirmed or affected first-degree relatives). Independent review of uterine tumor from 2 patients and staining for parafibromin on parathyroid tumors from 19 patients (13 adenomas, 6 carcinomas) was performed. RNA-sequencing was performed in 21 parathyroid samples (8 HPT-JT-related adenomas, 6 HPT-JT-related carcinomas, and 7 sporadic carcinomas with wild-type CDC73). Results We identified 68 patients from 29 kindreds with HPT-JT with median age at last follow-up of 39 [interquartile range, 29-53] years. A total of 55/68 (81%) developed primary hyperparathyroidism; 17/55 (31%) had parathyroid carcinoma. Twelve of 32 (38%) females developed uterine tumors. Of the 11 patients who had surgical resection for uterine tumors, 12/24 (50%) tumors were rare mixed epithelial mesenchymal polypoid lesions. Four of 68 patients (6%) developed solid kidney tumors; 3/4 had a CDC73 variant at p.M1 residue. Parafibromin staining of parathyroid tumors did not correlate with tumor histology or genotype. RNA-sequencing showed a significant association of HPT-JT-related parathyroid tumors with transmembrane receptor protein tyrosine kinase signaling pathway, mesodermal commitment pathway, and cell-cell adhesion. Conclusions Multiple, recurrent atypical adenomyomatous uterine polyps appear to be enriched in women with HPT-JT and appear characteristic of the disease. Patients with CDC73 variants at p.M1 residue appear predisposed to kidney tumors. Clinical Trial number NCT04969926
Abstract 10112: Association of Coronary Artery Disease Testing During Index Hospitalization for New-Onset Heart Failure With Thirty-Day Readmission Rates and Mortality
Webber, Fabrício Malaguez , Pinto, Edward R., Abreu, Adrian Da Silva De, Kittleson, M. , Zarich, Stuart, Jang, Sun-Joo , Yeo, Ilhwan , Abreu, Adrián Da Silva De

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.10112 Get It

Introduction: Testing for coronary artery disease (CAD) is recommended for patients with new-onset heart failure (HF). There are limited data on the association between testing for CAD during index hospitalization for patients with the new-onset HF and early readmission rates and readmission mortality. Hypothesis: CAD testing for new-onset HF during index hospitalization may reduce 30-day readmission rates and readmission-related mortality. Methods: Patients hospitalized for new-onset HF were identified from the Nationwide Readmission Database of the United States. Clinical characteristics, 30-day readmission rates, readmission-related mortality were compared in patients with or without testing for CAD during index hospitalization. CAD testing includes coronary angiography, coronary CT angiography, cardiac MRI, nuclear imaging or cardiac stress test. Results: Between January 2016 and November 2019, of 151,172 patients hospitalized for new-onset HF, 30,444 (20.1%) patients underwent testing for CAD during index hospitalization. Younger patients, males, and patients with HF with reduced ejection fraction (HFrEF) had more frequent testing for CAD. Only 9.5% of CAD-tested patients received percutaneous coronary intervention during the index hospitalization. Patients with CAD testing had lower 30-day readmission rates than those without testing (11.4% vs 14.3%, P<0.001; adjusted odds ratio (OR) 0.81, 95% confidence interval (CI) 0.76 to 0.87). Patients with CAD testing had lower 30-day readmission-related mortality rates than those without testing (0.5% vs 0.9%, P<0.001; adjusted OR 0.82, 95% CI 0.65 to 1.04). Readmission rate for HF at 30 days was 2.3% for patients with CAD testing vs 3.5% for those without testing (P<0.001; adjusted OR 0.67, 95% CI 0.59 to 0.76). There was a significant interaction between HF type (HFrEF vs HF with preserved EF) and CAD testing on 30-day readmission rates (P for interaction <0.001). Conclusions: Testing for CAD during index hospitalization for patients with new-onset HF was associated with reduced 30-day readmission rates. There was substantial decrease in readmission for HF and readmission-related mortality in patients who underwent CAD testing during index hospitalization.
Concurrent measurement of perfusion parameters related to small blood vessels and cerebrospinal fluid circulation in the human brain using dynamic dual‐spin‐echo perfusion MRI
Cao, Di , Sun, Yuanqi , Li, Yinghao , Pillai, Jay J. , Qiao, Ye , Knutsson, Linda , Sun, Yang-bai , Su, Pan , Knutsson, Linda , Pillai, Jay J , Sun, Yuanqi , Hua, Jun , Lu, Hanzhang , Zijl, Peter C.M. van

Mayo Clinic

NMR in Biomedicine | June 12, 2023 | Volume: 36 | Issue: 10 | Pages: No page available

10.1002/nbm.4984 | PMID 37308297 Get It

AbstractAccumulating evidence from recent studies has indicated the importance of studying the interaction between the microvascular and lymphatic systems in the brain. To date, most imaging methods can only measure blood or lymphatic vessels separately, such as dynamic susceptibility contrast (DSC) MRI for blood vessels and DSC MRI‐in‐the‐cerebrospinal fluid (CSF) (cDSC MRI) for lymphatic vessels. An approach that can measure both blood and lymphatic vessels in a single scan offers advantages such as a halved scan time and contrast dosage. This study attempts to develop one such approach by optimizing a dual‐echo turbo‐spin‐echo sequence, termed “dynamic dual‐spin‐echo perfusion (DDSEP) MRI”. Bloch simulations were performed to optimize the dual‐echo sequence for the measurement of gadolinium (Gd)‐induced blood and CSF signal changes using a short and a long echo time, respectively. The proposed method furnishes a T1‐dominant contrast in CSF and a T2‐dominant contrast in blood. MRI experiments were performed in healthy subjects to evaluate the dual‐echo approach by comparing it with existing separate methods. Based on simulations, the short and long echo time were chosen around the time when blood signals show maximum difference between post‐ and pre‐Gd scans, and the time when blood signals are completely suppressed, respectively. The proposed method showed consistent results in human brains as previous studies using separate methods. Signal changes from small blood vessels occurred faster than from lymphatic vessels after intravenous Gd injection. In conclusion, Gd‐induced signal changes in blood and CSF can be detected simultaneously in healthy subjects with the proposed sequence. The temporal difference in Gd‐induced signal changes from small blood and lymphatic vessels after intravenous Gd injection was confirmed using the proposed approach in the same human subjects. Results from this proof‐of‐concept study will be used to further optimize DDSEP MRI in subsequent studies.
Real‐World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Jacobson, Caron A. , Hemmer, Michael, Hu, Zhen‐Huan , Popplewell, Leslie , Best, Thomas M. , Beygi, Sara , Miao, Harry , Fu, Christine, Sun, Feifei , Xu, Hairong , Pasquini, Marcelo C. , Frank, Matthew J. , Ahmed, Nausheen , Lin, Yi

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 375-376

10.1002/hon.3164_271 Get It

Syk-dependent alternative homologous recombination activation promotes cancer resistance to DNA targeted therapy
Zhou, Qin , Tu, Xinyi , Hou, Xiaonan , Yu, Jia, Zhao, Fei , Huang, Jinzhou , Olson, Anna, Gao, Ming , Luo, Kuntian, Schoolmeester, Kenneth, Weroha, S. John , Wang, Liewei , Mutter, Robert W. , Kloeber, Jake, Zhu, Shouhai , Wu, Zheming , Zeng, Xiangyu , Weroha, John, Mutter, Robert, Lou, Zhenkun , Yu, Jia, Kloeber, Jake A. , Zhang, Yong , Sun, Chenyu , Lou, Zhenkun

Mayo Clinic

No container title available | June 9, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2922520/v1 | PMID 37333340 Get It

Abstract Enhanced DNA repair is an important mechanism of inherent and acquired resistance to DNA targeted therapies, including poly ADP ribose polymerase inhibition. Spleen associated tyrosine kinase (Syk) is a non-receptor tyrosine kinase known to regulate immune cell function, cell adhesion, and vascular development. Here, we report that Syk can be expressed in high grade serous ovarian cancer and triple negative breast cancers and promotes DNA double strand break resection, homologous recombination (HR) and therapeutic resistance. We found that Syk is activated by ATM following DNA damage and is recruited to DNA double strand breaks by NBS1. Once at the break site, Syk phosphorylates CtIP, a key mediator of resection and HR, at Thr-847 to promote repair activity, specifically in Syk expressing cancer cells. Syk inhibition or genetic deletion abolished CtIP Thr-847 phosphorylation and overcame the resistant phenotype. Collectively, our findings suggest that Syk drives therapeutic resistance by promoting DNA resection and HR through a novel ATM-Syk-CtIP pathway, and that Syk is a new tumor-specific target to sensitize Syk-expressing tumors to PARPi and other DNA targeted therapy.